WO2022218471A1 - Tktl1 inhibitoren für die antivirale therapie - Google Patents
Tktl1 inhibitoren für die antivirale therapie Download PDFInfo
- Publication number
- WO2022218471A1 WO2022218471A1 PCT/DE2022/100262 DE2022100262W WO2022218471A1 WO 2022218471 A1 WO2022218471 A1 WO 2022218471A1 DE 2022100262 W DE2022100262 W DE 2022100262W WO 2022218471 A1 WO2022218471 A1 WO 2022218471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tktl1
- oxythiamine
- benfo
- inhibitor according
- sars
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 54
- 238000002560 therapeutic procedure Methods 0.000 title description 16
- 230000000840 anti-viral effect Effects 0.000 title description 8
- 101000800498 Homo sapiens Transketolase-like protein 1 Proteins 0.000 claims abstract description 82
- 102100033108 Transketolase-like protein 1 Human genes 0.000 claims abstract description 81
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 21
- 230000009385 viral infection Effects 0.000 claims abstract description 8
- 208000009341 RNA Virus Infections Diseases 0.000 claims abstract description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 16
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 15
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 229940016667 resveratrol Drugs 0.000 claims description 14
- 235000021283 resveratrol Nutrition 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 13
- 239000000833 heterodimer Substances 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 238000013519 translation Methods 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- RNUAEUWXRHCGKX-UHFFFAOYSA-N oxythiamine chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)NC1=O RNUAEUWXRHCGKX-UHFFFAOYSA-N 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 5
- 150000003544 thiamines Chemical class 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- 238000006911 enzymatic reaction Methods 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 101150042043 TKTL1 gene Proteins 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000002133 anti-thiamin Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 75
- 102000014701 Transketolase Human genes 0.000 description 38
- 108010043652 Transketolase Proteins 0.000 description 38
- 241000700605 Viruses Species 0.000 description 37
- 241001678559 COVID-19 virus Species 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 31
- KTVPXOYAKDPRHY-SOOFDHNKSA-N D-ribofuranose 5-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KTVPXOYAKDPRHY-SOOFDHNKSA-N 0.000 description 17
- 230000009467 reduction Effects 0.000 description 15
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 230000029812 viral genome replication Effects 0.000 description 13
- 230000010076 replication Effects 0.000 description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 238000002832 anti-viral assay Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- -1 pentose phosphate Chemical class 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101100260730 Homo sapiens TKT gene Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000056458 human TKTL1 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to inhibitors of the transketolase TKTL1 (hereinafter referred to as “TKTL1 inhibitor” or “TKTL1 inhibitors”) for use in antiviral therapy, in particular the therapy of RNA viruses and in particular also of SARS-CoV-2 infections and Covid -19 diseases.
- TKTL1 inhibitor inhibitors of the transketolase TKTL1
- TKTL1 inhibitors for use in antiviral therapy, in particular the therapy of RNA viruses and in particular also of SARS-CoV-2 infections and Covid -19 diseases.
- SARS-CoV-2 corona virus
- SARS-CoV-2 In addition to the asymptomatic courses of infection, there are many people suffering from SARS-CoV-2 who have flu-like symptoms such as cough, sore throat, diarrhea or fever. In addition, in contrast to the flu, there are also symptoms such as loss of taste and other symptoms or failures associated with the function of nerve cells. Such neurologically associated symptoms such as limitations in cognitive performance, tiredness, chronic fatigue syndrome, which manifest themselves long after the acute SARS-CoV-2 infection has disappeared, represent a major health problem for those infected. A subgroup of SARS -CoV-2 infected people also develop pneumonia, sometimes bilateral pneumonia. Multiple organ failure resulting in death can also result from a SARS-CoV-2 infection.
- Such severe courses of a SARS-CoV-2 infection often lead to an overreaction, ie an excessive response of the immune system, in which, for example, immune cells migrate into the lungs and inhibit their functionality.
- Drugs that inhibit the activity of the immune system such as dexamethasone, show positive effects on the course of the disease. Nevertheless, a high proportion of those patients who have a severe course of SARS-CoV-2 infection die. So far none are sufficient Effective therapies are available that can be used to prevent or treat severe courses of Covid-19 disease.
- virus-specific therapy strategies based on virus-specific structures can quickly fail, because among the numerous virus mutants that occur naturally, some have also developed that are insensitive to the active substances in question or to vaccines. In principle, it is also not possible to predict which virus mutation or which virus will appear next and pose a danger to humans in the future. A timely development and planning of virus-specific therapy strategies is therefore very difficult or almost impossible.
- the genome of viruses consists of either RNA or DNA.
- the SARS-CoV-2 virus belongs to the RNA viruses.
- RNA viruses After infection and release of their viral RNA in a cell, RNA viruses depend on the replication (multiplication) of this viral RNA taking place quickly and in the largest possible quantity. Ribose-5-phosphate (R5P) from the host cell is required for this replication.
- R5P Ribose-5-phosphate
- DNA viruses also need R5P for their propagation in the host cell, because deoxyribose-5-phosphate, an essential component of their DNA, is produced from ribose-5-phosphate.
- R5P is provided via the pentose phosphate (PPP) pathway. According to conventional wisdom, this can be carried out both via the oxidative part and via the non-oxidative part of the PPP.
- Transketolases are key enzymes of the PPP. They form dimers and are activated by the binding of a molecule of thiamine diphosphate and a divalent cation. This transketolase enzyme activity can be altered through the formation of a heterodimer from a TKT and a transketolase-like-1 (TKTL1) protein (Li et al., 2019).
- Li et al. describe that the formation of TKTLl-TKT heterodimers allows cells to reprogram R5P metabolism when more R5P is needed, which is primarily the case for nucleotide and DNA synthesis during the S phase of the cell is, increased TKTL1 levels lead to increased formation of TKTLl-TKT heterodimers. These promote R5P production.
- Li et al. show that the basic R5P service of a cell is provided via the TKT-TKT homodimer.
- an “intracellular turbo program” is started via the expression of TKTL1 and the resulting TKT-TKTL1 heterodimer formation, which promotes increased formation of R5P in order to enable cell division and thus cell proliferation .
- the object of the present invention is to provide an agent for combating viral infections, in particular RNA virus infections, which is also particularly suitable for combating SARS-CoV-2 viruses.
- TKTL1 inhibitor at least one inhibitor of the transketolase TKTL1 (hereinafter referred to as “TKTL1 inhibitor”) for use in the medical-therapeutic treatment of virus infections (antiviral therapy), in particular the treatment (therapy) of RNA - Viral infections and in particular the treatment (therapy) of SARS-CoV-2 infections and associated diseases such as COVID-19.
- TKTL1 inhibitor at least one inhibitor of transketolase TKTL1 (“TKTL1 inhibitor” for short) as the active ingredient of an antiviral and in particular virostatic (virus-inhibiting) drug.
- inhibitor stands here in the context for a (i.e. in principle any) agent and in particular a (any) substance, namely substance or mixture of substances including pharmaceutical compositions, which is suitable for reducing the activity of TKTL1 to cause (induce) a polypeptide directly or indirectly in an individual or in cells of an individual.
- means or material substances include in particular:
- Inhibitors of the transcription of the TKTL1 gene for example substances that bind to the TKTL1 promoter and thereby limit or prevent its activity, such as resveratrol, which inhibits the TKTL1 promoter in a dose-dependent manner.
- Inhibitors of the translation of TKTL1 mRNA for example inhibitory RNAs such as antisense constructs, siRNAs, sh-RNAs, ribozymes.
- Inhibitors of the enzyme reaction of TKTL1 and/or the TKTL1-TKT heterodimer complex in particular drugs that inhibit this enzyme reaction restrict or prevent.
- drugs that inhibit this enzyme reaction restrict or prevent.
- These also include in particular antagonists of cofactors of TKTL1 polypeptides such as antithiamine compounds,
- Inhibitors of the formation of the TKTL1-TKT heterodimer complex in particular active substances which restrict or prevent the formation of the heterodimer.
- RNA is synonymous here for ribonucleic acid(s).
- DNA is synonymous here for deoxyribonucleic acid.
- the present invention is based on the surprising finding that inhibition of the enzyme TKTL1 and thus inhibition of the enzyme activity of the TKTL1/TKT heterodimer in human cells results in the proliferation (replication) of the virus RNA or virus DNA being significantly inhibited , but the host cell itself remains capable of surviving and the human organism suffers no permanent and irreversible damage.
- TKTL1 and/or the TKTL1/TKT heterodimer would be of a magnitude that, according to Bojkova et al. (2020) is required to slow down or prevent virus multiplication, leads to inhibition of cell division and thus to serious side effects including death.
- transketolases and in particular TKTL1 as a key enzyme in the regulation of cell cycle and cell division, are considered to be fundamentally relevant for the viability of cells, they appeared unsuitable as possible targets for an antiviral therapy strategy according to current teaching, because serious side effects were to be expected.
- TKTL1 inhibitors in the treatment of viral infections and in particular SARS-CoV-2 infections is based on the surprising finding that the biosynthesis of the virus nucleic acid and thus the virus replication (virus replication) in the human host cell by TKTL1- Inhibitors can be significantly inhibited or reduced without endangering the survival of the host cell and thus without any risk of damage to the human body.
- TKTL1 inhibitor interferes with the metabolism of the host cell and thus the entire human body and causes insufficient ribose-5-phosphate building blocks (R5P) to be available for virus replication and thus the virus Multiplication is slowed down or even completely prevented without irreversibly damaging the cell and the entire human body.
- R5P ribose-5-phosphate building blocks
- the use according to the invention of the TKTL1 inhibitors represents a therapy strategy which does not address virus-specific structures but rather factors which originate from the infected host cell and are required by the virus for its multiplication.
- an antiviral therapy strategy is available which, firstly, can be successfully used against a broad spectrum of viruses and, secondly, which is also effective in the case of mutations in the virus (virus mutants).
- This also allows protection against viruses that will only emerge in the future.
- the invention described allows protection against viruses without knowing their RNA or DNA sequence. In comparison to a vaccination, no lead time is required for the development of a drug, so that a therapy is available immediately. This enables the protection of civilization and mammals in general from existing and future viruses and diseases that emanate and will emanate from them. For the first time there is a protection of existence against viral diseases.
- the inhibitor is a substance or mixture of substances that is capable and suitable for specifically restricting or preventing the transcription of the TKTL1 gene.
- a substance is particularly suitable which is able and suitable to bind to the TKTL1 promoter of the cell and thereby restrict or prevent its activity.
- resveratrol in particular has proven to be a suitable inhibitor of the TKTL1 promoter (Kumar B, 2018).
- the inhibitor is a substance or mixture of substances which is/are suitable for specifically inhibiting the translation of the TKTL1 mRNA.
- at least one substance is particularly suitable that is selected from the group of TKTL1 mRNA-specific antisense constructs, TKTL1 mRNA-specific siRNAs, TKTL1 mRNA-specific sh RNAs, TKTL1 mRNA-specific ribozymes and other TKTL1 mRNA-specific inhibitory RNAs .
- the inhibitor is a substance or mixture of substances which is/are suitable for restricting or preventing the enzyme reaction of TKTL1 and/or the TKTL1-TKT heterodimer complex.
- At least one substance is particularly suitable for this purpose, which is selected from the group of antithiamine compounds and other antagonists, in particular from antagonists from the group of cofactors of the enzyme TKTL1.
- the TKTL1 inhibitor is an inhibitory thiamine analog. All previously known transketolase enzymes, including TKTL1, depend on the function of thiamine (vitamin Bl) as a coenzyme. Thiamine analogs such as oxythiamine act as thiamine antagonists and can be used to inhibit transketolases (cf. EP1354961A1).
- a preferred inhibitory thiamine analogue is the substance benfo-oxythiamine (B-OT).
- B-OT is a precursor ("prodrug", prodrug") of oxythiamine, can be administered orally and releases oxythiamine shortly after absorption into the mammalian organism. B-OT can reach all cells in all parts of the body via the bloodstream.
- oxythiamine can penetrate the blood-brain barrier and consequently can also be used successfully in viral infections in the brain
- the chemical structure (structural formula) of benfo-oxythiamine is known, e.g. from EP1354961A1.
- Bojkova et al. (2020) described the minimum concentration for the human Caco-2 cell lines at the cell culture level. In their investigations, Bojkova et al. (2020) that at least a 5 mM concentration of B-OT is required to inhibit SARS-CoV-2 virus proliferation in the SARS-CoV-2 infected Caco-2 cell lines.
- the present invention was based shown that administration of less than 35 mg B-OT per day and 70 kg body weight of the patient, ie less than 0.5 mg per kg body weight per day and accordingly less than a 1 nanomolar (1 nM) concentration of B- OT per kg body weight and per day is sufficient to inhibit the multiplication of SARS-CoV-2 viruses in the human body.
- the dose/dosage of the TKTL1 inhibitor benfo-oxythiamine is per kg of patient body weight and per day 7 pg ⁇ pg B-OT ⁇ 430 pg, preferably 14 pg ⁇ pg B-OT ⁇ 215 pg and more preferably 14 pg ⁇ pg B-OT ⁇ 130 pg.
- the benfo-oxythiamine in the case of benfo-oxythiamine as a TKTL1 inhibitor, is used in a dose of less than 0.5 mg, preferably less than 0.3 mg per kg of the patient's body weight and per day.
- B-OT benfo-oxythiamine
- the TKTL1 inhibitor is a substance or mixture of substances which is suitable for restricting or preventing the formation (formation) of the TKTL1-TKT heterodimer complex.
- Fig. 1 The reduction in SARS-Cov-2 viral load and survival of the Caco-2 cells after inhibition of TKTL1 translation using TKTL1 -specific siRNA
- Fig. 2 The reduction in SARS-Cov-2 viral load and survival of the Caco-2 cells after inhibition of TKT translation using TKT-specific siRNA
- Fig. 3 The reduction in the viral load of the human cytomegalovirus (HCMV) and survival of the Caco-2 cells after inhibition of TKTL1 translation using TKTL1 -specific siRNA
- Fig. 4 The reduction in the viral load of the human cytomegalovirus (HCMV) and survival of Caco-2 cells after inhibition of TKT translation using TKT-specific siRNA
- Fig. 5 The dose-dependent reduction in SARS-Cov-2 viral load and survival of Caco-2 cells after inhibition of the TKTL1 promoter using different doses of resveratrol
- Example 1 siRNA inhibition of (a) TKTL1 compared to siRNA inhibition of (b) TKT in SARS-CoV-2 infected mammalian cells
- SARS-CoV-2 infected Caco-2 cells were transfected with (a) human TKTL1 -specific siRNAs and (b) human TKT-specific siRNAs using a transfection reagent consisting of polycationic and neutral lipids (here METAFECTENE® from Biontex Laboratories GmbH, Kunststoff). and transfected with (c) an siRNA negative control (here the AllStars negative control siRNA from Qiagen, which according to the manufacturer does not show any homology to any known mammalian gene).
- siRNA negative control siRNA here the AllStars negative control siRNA from Qiagen, which according to the manufacturer does not show any homology to any known mammalian gene.
- siRNA or small interfering RNA, are short RNA molecules that do not code for proteins, but combine with complementary single-stranded RNA molecules, thereby preventing their normal function.
- siRNA sequences were used:
- TKT specific 5'-AAUGAUGGCUGUUGGCUGGTT-3'
- RTqPCR reverse transcriptase quantitative PCR
- RTqPCR reverse transcriptase quantitative PCR
- Western blot analyzes 72 h and 96 h after transfection in the SARS-CoV-2 infected and siRNA-transfected Caco -2 cells performed.
- the ability of the SARS-CoV-2 viruses to replicate after transfection of the Caco-2 cells with the various siRNAs was determined using immunostaining for the SARS-CoV-2 spike (S) protein. Using spike protein staining, the percentage of virus inhibition in cells transfected with (a) TKTL1 or (b) TKT siRNA compared to (c) cells transfected with the siRNA negative control was calculated.
- the cell viability of the SARS-CoV-2-infected Caco-2 cells transfected with the various siRNAs was determined using a methylthiazolyldiphenyltetrazolium bromide (MTT) assay.
- MTT methylthiazolyldiphenyltetrazolium bromide
- TKTL1-specific siRNA In the cells transfected with TKTL1-specific siRNA (compared to cells transfected with non-targeted control duplexes) there was an inhibition of TKTL1 translation.
- the inhibition of TKTL1 translation to a level at which cells remained viable led to a significant reduction in the replication ability of the SARS-CoV-2 viruses.
- HMCV human cytomegalovirus
- Example 2 siRNA inhibition of (a) TKTL1 compared to siRNA inhibition of (b) TKT in human cytomegalovirus (HCMV) infected mammalian cells
- HCMV human cytomegalovirus
- the Caco-2 cells were transfected with the siRNA sequences for TKTL1 and TKT mentioned in Example 1. Effective silencing was demonstrated using RTqPCR (reverse transcriptase quantitative PCR) and western blot analysis. These analyzes were carried out 72 h and 96 h after transfection. The viability of the HMCV-infected cells was determined using the MMT assay.
- the ability of the HCM viruses to replicate after transfection of the Caco-2 cells with the various siRNAs was determined using a fluorescence-based antiviral assay (Dal Pozzo et al 2008). Based on the EYFP signals of the recombinant viruses, the percentage of virus inhibition in the cells transfected with (a) TKTL1 or (b) TKT siRNA compared to the (c) cells transfected with the siRNA negative control was calculated. The results are shown in Figures 3 and 4.
- IC50 50% inhibitory concentration
- Example 4 Use of B-OT as a TKTLl inhibitor for the purpose of inhibiting the SARS-CoV-2 virus replication in the human body
- CRP C-reactive protein
- IL-6 interleukin-6
- the organic compound resveratrol (empirical formula C14H12O3) from the group of polyphenols is known to those skilled in the art as an inhibitor of the TKTL1 promoter.
- Kumar B. (2018) describes that treatment of HeLa cells with 50 mM resveratrol for 48 h led to a 75% reduction in TKTL1 promoter activity compared to untreated cells. At the same time, however, this also led to a significant decrease in the viability of the HeLa cells.
- resveratrol was used to prevent virus replication in SARS-CoV-2 infected Caco-2 cells.
- the SARS-CoV-2 infected Caco-2 cells were treated with different concentrations of resveratrol for 24 h.
- RTqPCR was performed. The results of this RTqPCR show a reduction in TKTLl mRNA depending on the resveratrol concentration used: the higher the concentration, the greater the reduction.
- Example 1 the survivability of the Caco-2 cells was determined using the MTT assay and the replication ability of the SARS-CoV-2 viruses using immunostaining for the SARS-CoV-2 spike (S) protein. SARS-CoV-2-infected Caco-2 cells without resveratrol treatment served as controls.
- Diaz-Moralli S Diaz-Moralli S, Aguilar E, Marin S, Coy JF, Dewerchin M, Antoniewicz MR, Meca-Cortes O, Notebaert L, Ghesquiere B, Eelen G, Thomson TM, Carmeliet P, Cascante M. (2016):
- TKTL1 Transketolase-Like Protein 1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023563119A JP2024514188A (ja) | 2021-04-14 | 2022-04-07 | 抗ウイルス治療のためのtktl1阻害剤 |
EP22719197.0A EP4322929A1 (de) | 2021-04-14 | 2022-04-07 | Tktl1 inhibitoren für die antivirale therapie |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102021109341.4A DE102021109341A1 (de) | 2021-04-14 | 2021-04-14 | TKTL1 Inhibitoren für die antivirale Therapie |
DE102021109341.4 | 2021-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022218471A1 true WO2022218471A1 (de) | 2022-10-20 |
Family
ID=81388854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2022/100262 WO2022218471A1 (de) | 2021-04-14 | 2022-04-07 | Tktl1 inhibitoren für die antivirale therapie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4322929A1 (de) |
JP (1) | JP2024514188A (de) |
DE (1) | DE102021109341A1 (de) |
WO (1) | WO2022218471A1 (de) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1354961A1 (de) | 2002-04-19 | 2003-10-22 | Johannes Dr. Coy | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen |
CN111214463A (zh) * | 2020-02-14 | 2020-06-02 | 南京大渊医美生物技术有限公司 | 一种白藜芦醇在制备抗SARS-CoV-2病毒药物的应用 |
CN111803472A (zh) * | 2020-07-03 | 2020-10-23 | 深圳市第三人民医院 | 一种抗新型冠状病毒药物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102020116980A1 (de) | 2020-06-27 | 2021-12-30 | TAVARGENIX GmbH | Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung |
-
2021
- 2021-04-14 DE DE102021109341.4A patent/DE102021109341A1/de active Pending
-
2022
- 2022-04-07 EP EP22719197.0A patent/EP4322929A1/de active Pending
- 2022-04-07 WO PCT/DE2022/100262 patent/WO2022218471A1/de active Application Filing
- 2022-04-07 JP JP2023563119A patent/JP2024514188A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1354961A1 (de) | 2002-04-19 | 2003-10-22 | Johannes Dr. Coy | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen |
CN111214463A (zh) * | 2020-02-14 | 2020-06-02 | 南京大渊医美生物技术有限公司 | 一种白藜芦醇在制备抗SARS-CoV-2病毒药物的应用 |
CN111803472A (zh) * | 2020-07-03 | 2020-10-23 | 深圳市第三人民医院 | 一种抗新型冠状病毒药物及其应用 |
Non-Patent Citations (13)
Title |
---|
ABBA YUSUF ET AL: "Antiviral Activity of Resveratrol against Human and Animal Viruses", ADVANCES IN VIROLOGY, vol. 2015, 1 January 2015 (2015-01-01), US, pages 1 - 7, XP055937935, ISSN: 1687-8639, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676993/pdf/AV2015-184241.pdf> DOI: 10.1155/2015/184241 * |
ATREIDES S PA ET AL: "Does Resveratrol Exhibit Antiviral Properties Against Cytomegalovirus Replication? | IOVS | ARVO Journals", ARVO ANNUAL MEETING ABSTRACT, 1 December 2002 (2002-12-01), pages 1 - 1, XP055937941, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2421569> [retrieved on 20220704] * |
BOJKOVA D, COSTA R, BECHTEL M, CIESEK S, MICHAELIS M, CINATL JR. J: "Targeting pentose phosphate pathway for SARS-CoV-2 therapy", BIORXIV, 2020, Retrieved from the Internet <URL:https://doi.org/10.1101/2020.08.19.257022> |
BOJKOVA DENISA ET AL: "Targeting pentose phosphate pathway for SARS-CoV-2 therapy", BIORXIV, 21 August 2020 (2020-08-21), pages 1 - 12, XP055936408, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.19.257022v1.full.pdf> [retrieved on 20220628], DOI: 10.1101/2020.08.19.257022 * |
DAL POZZO FANDREI GDAELEMANS DWINKLER MPIETTE JDE CLERCQ ESNOECK R: "Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus", JOURNAL OF VIROLOGICAL METHODS, vol. 151, 2008, pages 66 - 73, XP022708495, DOI: 10.1016/j.jviromet.2008.03.025 |
DIAZ-MORALLI SAGUILAR EMARIN SCOY JFDEWERCHIN MANTONIEWICZ MRMECA-CORTES ONOTEBAERT LGHESQUIERE BEELEN G: "A key role for transketolase-like 1 in tumor metabolic reprogramming", ONCOTARGET, vol. 7, no. 32, 2016, pages 51875 - 51897 |
GUPTA K. K.KHAN M. ASINGH S. K: "Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, 2020, Retrieved from the Internet <URL:http://doi.org/10.1089/jir.2019.0085> |
HELLER SMAURER GDWANKA CHOFMANN ULUGER ALBRUNS ISTEINBACH JPRIEGER J.: "Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to hypoxia and Ionizing Radiation", INT J MOL SEI., vol. 19, no. 8, 25 July 2018 (2018-07-25), pages 2168 |
KUMAR B: "Resveratrol inhibits expression of cancer-specific pentose phosphate pathway enzyme TKTL1", ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH, vol. 11, 2018, pages 332 |
LI Y, YAO CF, XU FJ, QU YY., LI JT, LIN Y, CAO ZL, LIN PC, XU W, ZHAO SM, & ZHAO JY: "APC /CCDHl synchronizes ribose-5-phosphate levels and DNA synthesis to cell cycle ", NATURE COMMUNICATIONS, vol. 10, 2019, pages 2502, Retrieved from the Internet <URL:https://doi.org/10.1038/s41467-019-10375-x> |
LU HZHU H.: "Effect of siRNA-mediated gene silencing of transketolase on A549 lung cancer cells", ONCOL LETT, vol. 14, no. 5, 2017, pages 5906 - 5912 |
PASQUEREAU SÉBASTIEN ET AL: "Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro", VIRUSES, vol. 13, no. 2, 1 January 2021 (2021-01-01), pages 354, XP055936463, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926471/pdf/viruses-13-00354.pdf> DOI: 10.3390/v13020354 * |
ZHU ZCAI TFAN LLOU KHUA XHUANG ZGAO G.: "Clinical value of immuneinflammatory parameters to assess the severity of coronavirus disease 2019", INT J INFECT DIS., vol. 95, 2010, pages 332 - 339, XP086180785, Retrieved from the Internet <URL:http://doi:10.1016/j.ijid.2020.04.041> DOI: 10.1016/j.ijid.2020.04.041 |
Also Published As
Publication number | Publication date |
---|---|
JP2024514188A (ja) | 2024-03-28 |
EP4322929A1 (de) | 2024-02-21 |
DE102021109341A1 (de) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boucek Jr et al. | The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. | |
EP2385835B1 (de) | Verwendung von deuteriumoxid zur behandlung viraler erkrankungen des auges | |
Wang et al. | MCTR1 enhances the resolution of lipopolysaccharide‐induced lung injury through STAT6‐mediated resident M2 alveolar macrophage polarization in mice | |
DE10313636A1 (de) | Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen | |
DE68909100T2 (de) | Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon. | |
EP1531826B1 (de) | Antidepressiva zur prophylaxe und therapie von zystischer fibrose | |
EP1599194A1 (de) | Verwendung von wirksubstanzen zur prophylaxe und/oder therapie von viruserkrankungen | |
EP3349741A1 (de) | Zusammensetzung mit antiviralem effekt | |
WO2022218471A1 (de) | Tktl1 inhibitoren für die antivirale therapie | |
DE60216292T2 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
EP4135701A1 (de) | Verwendung von co-enzym-antagonisten zur stoffwechselverlangsamung | |
WO2009103821A2 (de) | Mittel zur behandlung von virusinfektionen | |
Joksovic et al. | Inhibition of T‐type Calcium Current in the Reticular Thalamic Nucleus by a Novel Neuroactive Steroid | |
WO1999061045A1 (de) | Topisch anwendbares arzneimittel zur behandlung von virusinfektionen | |
EP2818167A1 (de) | Antiviral wirksame pharmazeutische Zusammensetzung | |
Niederberger et al. | Pharmacological aspects of pain research in Germany | |
EP2385834B1 (de) | Verwendung von deuteriumoxid zur behandlung virus-basierter erkrankungen des respirationstraktes | |
EP2964232B1 (de) | Piroxicam zur anwendung bei der prophylaktischen und therapeutischen behandlung von cmv-infektionen | |
DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege | |
WO2022127956A2 (de) | Verfahren zur identifizierung und/oder zum erhalten eines wirkstoffs zur behandlung und therapie der familiären amyotrophen lateralsklerose sowie verwendung eines wirkstoffs zur behandlung dieser erkrankung | |
EP4196099A1 (de) | Wirkstoffe und arzneimittel für die therapie von viruserkrankungen, insbesondere corona-infektionen, insbesondere covid-19 | |
DE212021000576U1 (de) | Vorbeugung oder Behandlung von Coronavirus-Infektionen | |
Scheck | Einfluss von gefrorenem Frischplasma auf die endotheliale Barrierefunktion | |
DE102020001998A1 (de) | Verfahren zur Zerstörung von RNA-haltigen Viren, einschließlich Coronaviren, einschließlich des Virus SARS CoV-2, das die Infektion der COrona-Virus-Krankheit 2019 (COVID-19) verursacht, sowie ein Verfahren zur Bekämpfung anderer Infektionskrankheiten, einschließlich bakterieller und anderer mikrobiologischer Art | |
EP2870968A1 (de) | Behandlung entzündlicher Darmerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22719197 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18554636 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023563119 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022719197 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022719197 Country of ref document: EP Effective date: 20231114 |